ロード中...
Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy characterized by excessive proliferation and accumulation of immature myeloid blasts in the bone marrow. AML has a very poor 5-year survival rate of just 16% in the UK; hence, more efficacious, tolerable, and targeted th...
保存先:
| 出版年: | J Clin Med |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7563273/ https://ncbi.nlm.nih.gov/pubmed/32932888 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9092934 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|